PMID- 23130928
OWN - NLM
STAT- MEDLINE
DCOM- 20130523
LR  - 20220318
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Print)
IS  - 1479-6694 (Linking)
VI  - 8
IP  - 10
DP  - 2012 Oct
TI  - Dendritic cell-based vaccines: barriers and opportunities.
PG  - 1273-99
LID - 10.2217/fon.12.125 [doi]
AB  - Dendritic cells (DCs) have several characteristics that make them an ideal 
      vehicle for tumor vaccines, and with the first US FDA-approved DC-based vaccine 
      in use for the treatment of prostate cancer, this technology has become a 
      promising new therapeutic option. However, DC-based vaccines face several 
      barriers that have limited their effectiveness in clinical trials. A major 
      barrier includes the activation state of the DC. Both DC lineage and maturation 
      signals must be selected to optimize the antitumor response and overcome 
      immunosuppressive effects of the tumor microenvironment. Another barrier to 
      successful vaccination is the selection of target antigens that will activate 
      both CD8(+) and CD4(+) T cells in a potent, immune-specific manner. Finally, 
      tumor progression and immune dysfunction limit vaccine efficacy in advanced 
      stages, which may make DC-based vaccines more efficacious in treating early-stage 
      disease. This review underscores the scientific basis and advances in the 
      development of DC-based vaccines, focuses on current barriers to success and 
      highlights new research opportunities to address these obstacles.
FAU - Cintolo, Jessica A
AU  - Cintolo JA
AD  - Department of Surgery & Harrison Department of Surgical Research, University of 
      Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA.
FAU - Datta, Jashodeep
AU  - Datta J
FAU - Mathew, Sarah J
AU  - Mathew SJ
FAU - Czerniecki, Brian J
AU  - Czerniecki BJ
LA  - eng
GR  - R01 CA096997/CA/NCI NIH HHS/United States
GR  - R01‑CA096997‑04A/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - *Cancer Vaccines/immunology/therapeutic use
MH  - Cell Lineage
MH  - Dendritic Cells/*immunology
MH  - Drug Delivery Systems
MH  - Humans
MH  - *Immunosuppression Therapy
MH  - Male
MH  - *Prostatic Neoplasms/drug therapy/immunology
MH  - Tumor Microenvironment/immunology
MH  - United States
MH  - United States Food and Drug Administration
PMC - PMC4260651
MID - NIHMS435666
COIS- Financial & competing interests disclosure The authors have no other relevant 
      affliations or financial involvement with any organization or entity with a 
      financial interest in or financial confict with the subject matter or materials 
      discussed in the manuscript apart from those disclosed. No writing assistance was 
      utilized in the production of this manuscript.
EDAT- 2012/11/08 06:00
MHDA- 2013/05/25 06:00
PMCR- 2014/12/09
CRDT- 2012/11/08 06:00
PHST- 2012/11/08 06:00 [entrez]
PHST- 2012/11/08 06:00 [pubmed]
PHST- 2013/05/25 06:00 [medline]
PHST- 2014/12/09 00:00 [pmc-release]
AID - 10.2217/fon.12.125 [doi]
PST - ppublish
SO  - Future Oncol. 2012 Oct;8(10):1273-99. doi: 10.2217/fon.12.125.